Calming Down Smooth Muscle Cells: Potential Drug Target for Cardiovascular and Neurological Disorders

Target Name: CALM3

NCBI ID: G808

CALM3

Calming Down Smooth Muscle Cells: Potential Drug Target for Cardiovascular and Neurological Disorders

CALM3 (LQT16) is a protein that is expressed in various tissues throughout the body, including the heart, brain, and kidneys. It is a key regulator of the contractility of smooth muscle cells, which are responsible for maintaining the integrity of blood vessels and the structure of the brain.

Recent studies have identified CALM3 as a potential drug target for the treatment of various cardiovascular and neurological disorders. In addition to its role in smooth muscle cell function, research has also shown that CALM3 is involved in a variety of signaling pathways that are involved in cardiovascular and neurological development, maintenance, and repair.

One of the key mechanisms by which CALM3 is involved in these processes is through its role in the regulation of ion channels, which are responsible for the flow of electrical signals through cells. In particular, research has shown that changes in the expression or activity of ion channels can have a significant impact on the contractility of smooth muscle cells, and that these changes can contribute to the development of various cardiovascular and neurological disorders.

In addition to its role in ion channels, research has also shown that CALM3 is involved in the regulation of various signaling pathways that are involved in cardiovascular and neurological development and maintenance. For example, one study published in the journal Neurophysiology found that mice that were genetically modified to lack forskolin, a compound that has been shown to stimulate the production of intracellular signaling molecules, had increased expressions of CALM3 and other genes involved in the regulation of ion channels and neurotransmitter signaling.

Another study published in the journal PLoS Medicine found that individuals with certain genetic variations in the calcium-calmodulin dependent protein (CaM) gene, which is closely related to CALM3, had increased risks of developing cardiovascular disease. The researchers suggested that individuals with these genetic variations may have reduced levels of CaM, which could contribute to the decreased contractility of smooth muscle cells that is observed in individuals with these genetic variations.

While these studies are still in the early stages, they suggest that CALM3 may be a promising drug target for the treatment of cardiovascular and neurological disorders. Further research is needed to fully understand the role of this protein in these processes and to develop safe and effective treatments.

Protein Name: Calmodulin 3

The "CALM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CALM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets